Jupiter Neurosciences, Inc. entered into a Securities Purchase Agreement on August 21, 2026, to sell 307,692 shares of common stock in a registered direct offering at $6.50 per share, generating approximately $2.0 million in gross proceeds before fees and expenses. The transaction is expected to close around August 24, 2026, with D. Boral Capital LLC acting as the placement agent for a 7.0% fee plus reimbursable expenses up to $75,000. Additionally, between August 14 and August 21, 2026, the company issued 107,920 shares to YA II PN, Ltd. under its Standby Equity Purchase Agreement for aggregate gross proceeds of $851,194. Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation.

Jupiter Neurosciences, Inc. closed a registered direct offering on August 24, 2026, issuing and selling 307,692 shares of common stock at $6.50 per share to raise approximately $2.0 million in aggregate gross proceeds. The company states that these proceeds bring its stockholders' equity above the $2.5 million minimum requirement for continued listing on The Nasdaq Capital Market, though it awaits formal confirmation from Nasdaq and warns of potential delisting if compliance is not evidenced by the next periodic report. Jupiter Neurosciences, Inc. operates in the biotechnology industry, focusing on the development of therapies for neurological disorders.

Jupiter Neurosciences, Inc. filed a Certificate of Amendment to its Delaware certificate of incorporation to effect a 1-for-75 reverse stock split of its common stock. The split became effective at 4:01 p.m. Eastern Time on August 6, 2026, with post-split trading commencing on the Nasdaq Capital Market on August 7, 2026. This action reduces outstanding shares from approximately 57.8 million to roughly 770,081 and aims to restore compliance with Nasdaq’s minimum bid price requirement. Fractional shares are cashed out based on the closing price on August 6, 2026. Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing therapies for neurological disorders.

Jupiter Neurosciences, Inc. issued and sold 11,470,000 shares of common stock to Yorkville II PN, Ltd. under a Standby Equity Purchase Agreement between May 14, 2026, and July 24, 2026. The transaction generated approximately $3.6 million in aggregate gross proceeds, with the per-share price set at 97% of the lowest daily volume-weighted average price during the relevant pricing periods. Following these issuances, the company reported 56,520,143 shares of common stock issued and outstanding as of July 28, 2026. Jupiter Neurosciences, Inc. operates in the biotechnology industry, focusing on the development of therapies for neurological disorders.

Jupiter Neurosciences, Inc. stockholders' 2026 Annual Meeting results show that stockholders' approval of an amendment to the certificate of incorporation to effect a reverse stock split between 1:10 and 1:100 ratio. Additionally, stockholders' approval of an amendment to the 2025 Equity Incentive Plan to increase the following: 12.5 million SEPA Shares issued to Yorkville pursuant to the SEPA, 5,250,000 shares of common stock available for sale under the share incentive plan. Jupiter Neurosciences, Inc. is a healthcare company that develops neurosciences.**